Abbvie shares rising in New York on eczema drug news
The news led to a fall in rival Regeneron (NASDAQ:REGN), which shed over 5.6%
Company
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
37 stories · page 2 of 2
Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Amgen up after judge rules rivals must pull a competing cholesterol drug off the market
District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
US stocks clinch record highs, Dow skids (just) shy of 20,000 after jobs report
US stocks clinched fresh record highs on Friday, with the Dow coming within a hair’s breadth of 20,000 – which can only have been helped by Goldman Sach’s shares driving 1.5% higher
US stocks end lower as oil wanes, Fed in focus
US stocks ended lower on Monday as oil price gains waned and investors grew ever more anxious ahead of the Fed’s rate decision mid-week
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
US stocks hit record highs as Dow adds 300 points, but pharma sink
US stocks hit fresh record highs on Wednesday, with the S&P 500 marking its biggest single-day gains since the presidential elections, as investors largely shrugged off declines in health care stocks
Pharmas Regeneron and Teva shares hit by FDA order
Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Teva and Regeneron to commercialise Fasinumab for chronic pain
Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. are teaming up to develop and commercialise globally commercialize fasinumab, Regeneron’s investigational NGF antibody in Phase 3 clinical development for osteoarthriti
Archive
S&P 500 caps solid week
The S&P enjoyed it best week for a month, while small and mid-caps also made progress.
Stocks sleep-walking towards the weekend
The March jobs report has perked up the blue-chips a little but the rest of the market seems indifferent
Wall Street extends slump as Fed president indicates September rate hike likely
Wall Street fell deeper today, as one Federal Reserve president indicated a September interest-rate hike is likely unless there’s a significant deterioration in the economy. The S&P 500 (INDEXSP:.INX) skidded 0.2 percent to 2,094.
U.S. stock-index futures drop as investors eye jobs report; CVS slides
U.S. stock index futures were lower today as investors await key jobs reports due later in the week. Futures for the Dow Jones Industrial Average lost 0.2 percent to 17,475, while those for the S&P 500 index skidded 0.3 percent to 2,085
Wall Street breaks 5-day losing run as investors look for tomorrow’s Fed statement
U.S. stocks halted the five-day losing streak today, as investors looked past softer economic reports and a continued rout in China’s stock market, and waited for the outcome of the two-day Federal Reserve. The S&P 500 (INDEXSP:.I
Wall Street on track to end 5-day rout as China selloff stalls
Wall Street is poised to end a five-session losing streak, amid better-than-forecast earnings, as Chinese equities pulled back from a selloff, and ahead of a highly anticipated Federal Reserve meeting. Futures for the Dow Jones Industrial A